

ASTRAZENECA AB and ASTRAZENECA	Α
PHARMACEUTICALS (PHILS.), INC.,	

Complainants,

-versus-

IPV No. 10-2012-00005 For: Patent Infringement, Damages and Injunction with applications for Temporary Restraining Order and/or Preliminary Injunction

GLOBE LINK PHARMA, INC. and REGISTRADE PARTNERS CORP.,

Respondents.

NOTICE OF DECISION

**ESGUERRA & BLANCO** 

Counsel for Complainants 4th and 5th Floor, S & L Building Dela Rosa cor. Esteban Sts. Legaspi Village, Makati City

ATTY. L. IMPERIAL SAMAR

Counsel for the Respondent Globe Link (Pharma, Inc.) Unit 807 Antel Global Corporate Center

92A West Avenue, Barangay Philam

Quezon City

KAPUNAN TAMANO JAVIER & ASSOCIATES B-Angel 7/25/13

Counsel for the Respondent Registrade Partners Corporation Unit 807 Antel Global Corporate Center Dona Julia Vargas Avenue, Ortigas Center Pasig City

**GREETINGS:** 

Please be informed that Decision No. 2013 - 11 dated September 19, 2013 (copy enclosed) was promulgated in the above entitled case.

Taguig City, September 19, 2013.

For the Director:

Q. Oate ATTY. EDWIN DANILO A. DATING

Director III Bureau of Legal Affairs

Republic of the Philippines INTELLECTUAL PROPERTY OFFICE

Intellectual Property Center, 28 Upper McKinley Road, McKinley Hill Town Center Fort Bonifacio, Taguig City 1634 Philippines T: +632-2386300 • F: +632-5539480 • www.ipophil.gov.ph



ASTRAZENECA AB and ASTRAZENECA} PHARMACEUTICALS (PHILS.), INC., }

Complainants,

- versus -

GLOBE LINK PHARMA, INC. and REGISTRADE PARTNERS CORP.

Respondents.

IPV No. 10-2012-00005

For: Patent Infringement, Damages and Injunction with applications for Temporary Restraining Order and/or Preliminary Injunction

Decision No. 2013-

## PARTIAL DECISION BASED ON COMPROMISE AGREEMENT

ASTRAZENECA AB and ASTRAZENECA PHARMACEUTICALS (PHILS.), INC. ("Complainants") filed on 10 April 2012, a complaint against GLOBE LINK PHARMA, INC. and REGISTRADE PARTNERS CORP. ("Respondents") for alleged Patent Infringement. The Complainants assail the Respondents' alleged unauthorized importing, promoting, distributing, selling and offering for sale their own product containing Esomeprazole Magnesiun Trihydrite which allegedly infringes on Complainants' Letters Patent Nos. 1-1994-48276 and 1-1998-01198.

This Bureau issued a Notice to Answer and served upon a copy thereof to Respondents on 11 April 2012. On 15 August 2013, the Complainants and Respondent Globe Link Pharma, Inc. filed a Joint Motion to Render Partial Judgment Based on Compromise, the pertinent portions thereof reads, as follows:

NOW, THEREFORE, for and in consideration of the foregoing premises, the Parties hereto have agreed as follows:

- "1. GLP admits that the Esomeprazole Patents are valid and enforceable. GLP also recognizes, respects and will respect and nor violate the First Party's exclusive right to use, register, license, distribute, sell and maintain the Esomeprazole Patents in the Philippines.
- "2. In consideration of the First Party's agreement not to pursue its claim for damages in its infringement case against GLP, GLP agrees as follows:
  - a. GLP shall not manufacture, use, import, export, market, sell, license or otherwise distribute products containing the compounds protected by the Esomeprazole Patents in the Philippines without prior written authorization from the First Party;

1



- b. GLP shall recall from the market all products containing Esomeprazole compounds that it sold and distributed, including the materials used in the promotion, sales and distribution of said products containing Esomeprazole compounds, to be disposed of in such manner as may be deemed appropriate by the First Party;
- c. GLP shall not seek to register, obtain a registration for or maintain a registration for products containing Esomeprazole compounds with the FDA or the IPO until the expiration of the last Esomeprazole Patent;
- d. GLP shall not challenge the use of, nor seek to invalidate the registration of, or file or pursue any opposition to any registration or application for the intellectual property registrations owned by AZAB or its affiliates in relation to products containing Esomeprazole compounds;
- e. GLP shall fully cooperate with the continuing investigation and prosecution of persons or entities involved or engaged in the infringement of AZAb's and AZ Phil's patent, exclusive distributorship and other intellectual property rights; and
- f. As soon as commercially reasonable, and in no event later than sixty (60) days after the execution of this Agreement, GLP shall: (i) remove from all internet websites under its control, or over which it may reasonably exercise control, all references to any designation that consists of or products containing Esomeprazole compounds, including any references that may be contained in metatext; and (ii) cancel all registrations in its possession or under its control for domain names that consist of or contain the term Esomeprazole.
- "3. In case of breach of any of the terms as as described above by GLP or any of its affiliates, officers, agents or assigns, GLP shall pay or cause to be paid to the First Party the sum of FIVE MILLION PESOS (P5,000,000.00) as and by way of non-exclusive liquidated damages, without prejudice to any other available legal remedies.
- "4. The parties hereby undertake to file the necessary motion for judgment in IPV Case No. 10-2012-00005 based on this Compromise Agreement, and the Parties agree that this Agreement shall form the basis of an appropriate judgment to be entered in said action. The parties further obligate themselves to do any and all necessary action to cause the approval of this Agreement by the Bureau of Legal Affairs (BLA) Director.
- "5. The parties warrant that he signatories hereto have been duly authorized and granted full power and authority to compromise or settle and execute this Agreement and all documents necessary in connection therewith as shown by the attached Secretary's Certificates and Special Power of Attorney which are hereby made integral part of this Agreement.
- "6. The Parties represent that they entered into this Agreement freely, voluntarily, in good faith, and with full knowledge and understanding of their rights and obligations hereunder.
- "7. The Parties agree to be bound by the terms and conditions of this Agreement, and agree to impose the obligations under this Agreement upon their respective agents,

K

employees, affiliates, subsidiaries, related companies, licensees, successors in rights and assignees. The parties undertake to transmit the obligations resulting hereof to their respective agents, employees, affiliates, subsidiaries, related companies, licensees, successors in rights and assignees.

- "8. The Parties agree that each will bear its own costs and attorney's fees in this matter.
- "9. This Agreement has been prepared by the combined efforts of all the Parties and their respective attorneys and may only be amended in writing by a documents so designated and executed by the Parties hereto.
- "10. There are no representations, promises, warranties, covenants or undertakings other than those expressly set forth herein and this writing represents the entire understanding of the parties. In the event that any portion of this Agreement is adjudged invalid or unenforceable, then the surviving portion of this Agreement shall constitute the Agreement, unless such surviving portions fail to retain the essential understanding between the parties, whereupon the Agreement shall be treated as terminated by mutual consent of the parties.
- "11. Waiver by a party of any breach, or failure by a party to enforce the terms and conditions of this Agreement, at any time, shall not in any way affect, limit or waive the right of that party to enforce strict compliance by another party with respect to any other or further breach of any term or condition hereof.
- "12. All notices and other communications required or permitted under this Agreement shall be made as follows:

In the case of AZAB and AZ Phils.:

16<sup>th</sup> Floor, Net 3 Center, 3<sup>rd</sup> Avenue corner 30<sup>th</sup> Street, E-Square Zone, Crescent Park West, Bonifacio Global City, Taguig City
Attention: Regional Legal Counsel, Asia Area
Fax: +63 (2) 777 87 96

With a copy to:

Esguerra & Blanco Law Offices 4<sup>th</sup> Floor, S&L Building, Dela Rosa corner Esteban Streets, Legaspi Village, Makati City 1229 Fax: (632) 8138185

In the case of GLP:

Globe Link Pharma, Inc. Unit A-3 3<sup>rd</sup> Floor, Prosperity West Center Building 92-A West Avenue, Quezon City 1104 Fax: (632) 9277705

M

With a copy to:

L. Imperial Samar Unit A-3 3<sup>rd</sup> Floor, Prosperity West Center Building 92-A West Avenue, Quezon City 1104"

This Bureau evaluated the COMPROMISE AGREEMENT and finds that the same has been duly entered into by the parties with the terms and conditions thereof not contrary to law, morals, good customs, public order or public policy.

Accordingly, an approved Compromise Agreement shall have the effect of a decision or judgment on the case between the Complainants and Respondent Globe Link Pharma, Inc. and shall be enforced accordingly in accordance with the pertinent rules of IPO and the Rules of Court.<sup>1</sup>

WHEREFORE, premises considered, the Complainants and Respondent Globe Link Pharma, Inc.'s Compromise Agreement is hereby APPROVED. Accordingly, with the approved COMPROMISE AGREEMENT having the force and effect of a decision or judgment, the parties are enjoined to faithfully comply with the terms set forth therein.

SO ORDERED.

Taguig City, 19 September 2013.

Atty. NATHANIEL S. AREVALO
Director IV
Bureau of Legal Affairs

/vanj..MVD

Office Order No. 154 Series of 2010.